HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.
With support from Alcon, FedEx, and OMEGA, the Orbis Flying Eye Hospital returns to Peru to carry out a training project in the city of Arequipa.AREQUIPA,...
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.
DUBAI, United Arab Emirates, June 14, 2026 (GLOBE NEWSWIRE) -- Ruvi AI, the AI-powered blockchain ecosystem combining artificial intelligence, decentralized infrastructure, creator monetization, and tokenized participation, has announced that Phase 3 of its ongoing token presale has now reached 90% completion.
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...
FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.
MIAMI, June 14, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs, peneraju dalam dana dagangan bursa bertema dan berleveraj, hari ini mengumumkan bahawa dagangan saham Defiance Daily 2X Space ETF (Cboe BZX: SPCL) telah digantung buat sementara waktu oleh Cboe BZX Exchange, Inc. (“Bursa”).
Vancouver, Canada, June 14, 2026 (GLOBE NEWSWIRE) --
$100 no deposit bonus 200 free spins real money promotions remain widely discussed as players look for practical ways to evaluate free spins casinos before making a deposit. As 50 no deposit free spins for real money bonus continue attracting players, many users are taking a closer look at promotional details and the overall value offered by no deposit bonus casinos.
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...
SHANGHAI, June 14, 2026 (GLOBE NEWSWIRE) -- French outdoor brand Salomon has officially unsealed the latest instalment of the ROAD TO THE FUTURE programme at the Anfu concept store in Shanghai, China. This event unveiled the full launch of the 2026 Road to the Future Design Competition. Guest designer Uma Wang joins eight emerging designers to debut exclusive collaborative footwear designs, coinciding with the public opening of the project’s in-store display and official launch of public voting phase. Salomon China brand ambassador Bai Jingting attended the opening event, uniting established designers, cross-industry professionals and industry medias to dissect the evolving trajectory of the emerging boundaries of outdoor and fashion industry. In the future, Salomon will continuously explore the boundaries of outdoor aesthetics through creativities.